Editorial Commentary HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer Toshimitsu Yamaoka, Junji Tsurutani, Hironori Sagara, Tohru Ohmori
